- Novel Carbohydrate Binding Modules (mCBMs) block entry into airway cells for a range of viruses causing respiratory tract infections.
- Results show Pneumagen’s mCBMs demonstrate activity against coronaviruses.
28th April 2020 – St Andrews, Scotland – Pneumagen Ltd, a University of St Andrews spinout, focused on treating infectious disease and oncology by targeting the human glycome, today announced results from three separate in vitro studies into preventing coronavirus infections including SARS-CoV-2 infection the cause of COVID-19 using Neumifil™ and other first-in-class multivalent Carbohydrate Binding Modules (mCBMs), generated using its proprietary GlycoTarge™ platform.
Working closely with Public Health England’s Porton facility, and separately the University of Glasgow’s MRC Centre for Virus Research, Pneumagen has tested the activity of its mCBMs against coronaviruses, using plaque reduction assays. At Porton and the University of Glasgow, Pneumagen’s mCBMs were found to reduce the number of SARS-CoV-2 plaques in these assays when the mCBMs were used in both prevention and treatment of infection. This builds on the company’s own work, with a different clinically relevant coronavirus that can cause the common cold where a plaque reduction assay also demonstrated antiviral activity for mCBMs.
Pneumagen’s lead mCBM, Neumifil™, is already being developed for the universal treatment of respiratory tract infections (RTIs) including Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV), and now coronaviruses. Neumifil’s novel mechanism of action, masking glycan receptors in patients’ airways thereby preventing the entry of the virus, has the potential to revolutionise the treatment of RTIs by providing clinicians with the opportunity to offer patients total protection against any circulating viral strain.
Douglas Thomson, CEO of Pneumagen, said: “Today’s positive results from in vitro studies of our mCBMs against coronaviruses show that glycan binding has the potential to prevent and treat infection. This further supports the value of our universal therapeutic modality to block access to lung cells of SARS-CoV-2, as well as other viruses, that causes respiratory tract infections, providing the potential for a pan-viral respiratory product. Our goal is now to rapidly begin clinical testing for the prevention and treatment of COVID-19.”
Pneumagen is using its platform technology, GlycoTarge, to develop glycan targeted carbohydrate-binding module domains (mCBMs) derived from bacterial glycosidases as a new universal therapeutic modality for the prevention and treatment of respiratory tract infections (RTIs). These engineered mCBMs have been shown to prevent and treat respiratory infections by binding to epithelial cell surface glycan receptors present in the respiratory tract, used by several pathogens for entry.
Pneumagen’s lead product, Neumifil, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), and coronavirus COVID-19 infections. When administered intranasally in preclinical models, Neumifil has demonstrated prevention, treatment and post-exposure prophylaxis of IFV and RSV infection with no observed toxicity. Pneumagen’s mCBMs, in development for cancer, are known as Neumonco. In vitro data have demonstrated that mCBMs target cancer cells, reducing cell proliferation, migration, metabolism and differentiation.
The Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Please visit www.pneumagen.com for more information.
Katja Stout, Scius Communications
Douglas Thomson, Pneumagen